A

M

ANGUITA SÁNCHEZ , Manuel

Last name: ANGUITA SÁNCHEZ

First name: Manuel

November 22, 2023 (v1)

Publication

Metadata-only

Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

Sanmartín Fernández, Marcelo Anguita Sánchez, Manuel Arribas, Fernando

atrial fibrillation (AF) treated with rivaroxaban and to improve the accuracy of 2MACE. Methods: This was a post-authorization and observational study of AF adults treated with rivaroxaban for ≥ 6 months. The primary endpoint was any of the major adverse cardiac events (MACE), namely, cardiovas cular death, non-fatal myocardial infarction, and...

Uploaded on: November 25, 2023